Copiktra (duvelisib) — United Healthcare

Initial criteria

• Diagnosis of peripheral T-cell lymphoma
• Used as initial palliative intent therapy OR used as second-line and subsequent therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Copiktra therapy

Approval duration

12 months